The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented earlier this month at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented Friday at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.

In an effort to compile and summarize the latest knowledge about immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients — ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.

The Buffalo Sabres today announced the team, in partnership with Roswell Park Comprehensive Cancer Center, will again take part in the NHL’s Hockey Fights Cancer™ program during the team’s home game against the San Jose Sharks on Tuesday, Nov. 27, at 7 p.m.

Roswell Park has formed an academic cooperation agreement with the Jagiellonian University (JU) in Kraków, Poland. The collaboration will see the two centers exchanging staff, students and scientific resources to jointly undertake basic, translational and clinical research in order to advance the development of cancer therapies to benefit patients worldwide.